Prostate Cancer
Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer.
January 11, 2024
Positive family history as a predictor for disease outcomes after radical prostatectomy for nonmetastatic prostate cancer.
January 11, 2024
Role of Radiotherapy and Hormone Therapy in Patients with Node-Positive Locally Advanced Prostate Cancer.
January 11, 2024
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
January 10, 2024
Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
January 10, 2024
A population-based study of cardiovascular disease mortality risk in US cancer patients.
January 10, 2024
Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC.
January 10, 2024
Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer.
January 10, 2024
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
January 9, 2024
A qualitative study of barriers and facilitators for health behavior change in low-income men with prostate cancer.
January 9, 2024
Benefit of dynamic contrast-enhanced (DCE) imaging for prostate cancer detection depending on readers experience in prostate MRI.
January 9, 2024
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
January 9, 2024